Quince Therapeutics, Inc.
Last verified 2026-06-14. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $114.7Mattributed |
|---|---|
| Latest round | Funding round, $114.7M, 2026-06-11attributed |
| Founded | unknown |
| Headquarters | South San Francisco, CA |
| Industry | biotechnology |
| Stage | unknown |
| Website | quincetx.com |
Quince Therapeutics is a late-stage biotech treating rare diseases via its AIDE platform, which encapsulates drugs inside a patient's own red blood cells. Its lead program targets Ataxia-Telangiectasia, a rare genetic disorder. Its edge is using autologous red blood cells to improve tolerability and half-life while cutting immunogenicity.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-06-11 | Funding round | $114.7M | undisclosed |
Detected tech stack
adobe fonts, apache, apache http server, imagesloaded 4.1.4, jquery 3.7.1, jquery migrate 3.4.1, mysql, parallax.js, php, typekit, wordpress 6.5.8, wordpress block editor
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $114.7M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $114.7M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | quincetx.com, read 2026-06-14 |
| Description | self-reported | quincetx.com, read 2026-06-14 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $114.7M, 2026-06-11 → Funding round, $114.7M, 2026-06-11, sec-edgar, No document URL on file | Latest round | seed, $114.7M, 2026-06-11 → Funding round, $114.7M, 2026-06-11 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes